Results 121 to 130 of about 51,359 (249)
Systemic Therapy Management Strategies for Early‐Stage Breast Cancer in Australia
Asia-Pacific Journal of Clinical Oncology, EarlyView.Advances in systemic therapy for early‐stage breast cancer in Australia highlight genomic‐guided decisions, subtype‐specific strategies, and emerging targeted and immunotherapies, shaping personalized and de‐escalated treatment approaches. ABSTRACT Breast cancer is the most common cancer among Australian women, with early‐stage disease (Stages I, II ...
Nicholas Zdenkowski +6 more
wiley +1 more source
Targeting hexokinase 2 to induce breast cancer cell senescence
British Journal of Pharmacology, EarlyView.Background and Purpose Hexokinase 2 (HK2) is a key enzyme linked to high tumour cell proliferation. Its inhibitors such as 3‐bromopyruvic acid (3‐BP) induce cancer cell death, highlighting HK2 modulation as potential anti‐cancer treatment. However, standard chemotherapies often cause the emergence of senescent cancer cells, which goes along with cell ...
Helmut Bischof +8 more
wiley +1 more source
Targeting the untargetable? Nodal expression in TNBC [PDF]
Cell Cycle, 2016 Eric D, Young, Danny R, Welch
openaire +2 more sources
Cancer pain: current practice and emerging targets
British Journal of Pharmacology, EarlyView.Cancer pain (CP) arises from a complex interplay between the tumour and its microenvironment. Many patients experience a mixed pain phenotype that encompasses nociceptive, neuropathic and neuroinflammatory mechanisms, and vary across tumour type and disease stage. Despite decades of intensive research, the mainstay of cancer pain treatment is still non‐
Yi Ye +5 more
wiley +1 more source
The multifaceted roles of mitochondria and their therapeutic transformation: a new perspective on triple-negative breast cancer treatment. [PDF]
Front OncolYang S, Wang L, Nie J.
europepmc +1 more source
Cancer Science, EarlyView.Multi‐region sequencing of 57 BRCA1‐associated breast cancers identified TP53 as the dominant initial driver, defining a triple‐negative subgroup with biallelic BRCA1 loss and elevated genomic instability. TP53 truncating mutations were enriched in BRCA1 carriers and linked to reduced HRD, EMT activation, and a trend toward worse survival.
Li Hu +13 more
wiley +1 more source
SLC2A9-Mediated Uric Acid Homeostasis Modulates Apoptosis in TNBC. [PDF]
Breast Cancer (Dove Med Press)Chen P +6 more
europepmc +1 more source
Pleiotropic Roles of FBXO11 in Tumorigenesis: Implications for Targeted Therapy
Cancer Science, EarlyView.This complex comprises of scaffold CUL1, SKP1, RBX1 and FBXO11 receptor. The substrate is phosphorylated by specific kinase enzyme and recognized by the substrate recognition domain. FBXO11 targets numerous substrates for ubiquitination and degradation, FBXO11 substrates mainly include Snail, ZEB1, p53, BCL6, CDT2, CIITA, Cdc25a, hnRNPA2B1, SAMD1 and ...
Yuqi Zhang +6 more
wiley +1 more source
Salidroside-Based Nanomedicines for Triple-Negative Breast Cancer: From Molecular Mechanisms to Clinical Translation. [PDF]
Breast Cancer (Dove Med Press)Ma X, Dang S, Wang H, Xia L, Ma P, Qi Y.
europepmc +1 more source
Cancer Science, EarlyView.Adipocyte‐derived palmitic acid induces ZDHHC15‐mediated PPARγ S‐palmitoylation at Cys159, triggering its proteasomal degradation and promoting breast cancer malignancy with rosiglitazone resistance. Inhibition of PPARγ S‐palmitoylation by 2‐bromopalmitate suppresses breast cancer progression and synergistically enhances rosiglitazone efficacy ...
Geon Ho Moon +6 more
wiley +1 more source